Purchase this article with an account.
Yuka Okada, Kumi Shiai, Masayasu Miyajima, Peter S Reinach, Shizuya Saika; Systemic administration of TRPV4 antagonist suppresses corneal inflammation and scarring induced by alkali burning in mice.. Invest. Ophthalmol. Vis. Sci. 2014;55(13):4683.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
We previously reported that in mice transient receptor potential vanilloid 4 (TRPV4) gene ablation improved the corneal wound healing response to alkali burning (ARVO, 2011). We here tried to reproduce its favorable effects by using a TRPV4 antagonist.
Three microliters of 1 N NaOH were applied to the right eye of WT (n = 24) mice to produce an ocular surface alkali burn under general anesthesia. The mice received intraperitoneal injection of either a TRPV4 receptor antagonist, HC-067047 (10 mg/kg, daily), or its vehicle. The eyes were processed for histology/immunohistochemistry.
Stroma of the TRPV4 antagonist-treated WT mice healing corneas were less opaque as compared with those of untreated WT mice at 5 to 20 days post-alkali burn. Hematoxylin-eosin histological staining indicated more marked inflammation in the thickened stroma of untreated WT mice. Immunohistochemical examination showed less population of cells of immunoreaction for α-smooth muscle actin expression, F4/80, myeloperoxidase and active TGFβ1 in the TRPV4 antagonist-treated WT mice after alkali burn.
Systemic TRPV4 antagonist administration reproduced the KO healing phenotype; suppression of inflammation and scarring in the alkali-burned corneal stroma. This favorable outcome could mean that TRPV4 is a potential drug target for reducing the adverse effects of TRPV4 activation by injury.
This PDF is available to Subscribers Only